IRIS Institutional Research Information System - OPENBS Open Archive UniBS

FRANCESCHINI, Franco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.274
EU - Europa 10.316
AS - Asia 8.863
SA - Sud America 1.907
AF - Africa 189
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 15
AN - Antartide 1
Totale 36.588
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.973
IT - Italia 4.590
SG - Singapore 3.159
CN - Cina 2.762
BR - Brasile 1.614
UA - Ucraina 1.480
HK - Hong Kong 1.173
DE - Germania 1.161
VN - Vietnam 610
FI - Finlandia 561
GB - Regno Unito 510
RU - Federazione Russa 416
TR - Turchia 372
IE - Irlanda 368
FR - Francia 340
PL - Polonia 205
IN - India 196
CA - Canada 149
SE - Svezia 136
BD - Bangladesh 131
NL - Olanda 116
AR - Argentina 113
MX - Messico 91
ZA - Sudafrica 78
ES - Italia 77
IQ - Iraq 73
AT - Austria 65
JP - Giappone 61
BE - Belgio 48
ID - Indonesia 45
EC - Ecuador 44
PK - Pakistan 42
VE - Venezuela 36
MA - Marocco 30
SA - Arabia Saudita 30
CZ - Repubblica Ceca 27
EG - Egitto 26
LT - Lituania 26
CO - Colombia 24
EE - Estonia 24
AE - Emirati Arabi Uniti 23
JO - Giordania 23
PY - Paraguay 22
UZ - Uzbekistan 22
RO - Romania 20
AU - Australia 19
AZ - Azerbaigian 19
CH - Svizzera 18
CL - Cile 18
IL - Israele 16
UY - Uruguay 16
KE - Kenya 15
EU - Europa 14
HR - Croazia 14
KZ - Kazakistan 14
PE - Perù 13
GR - Grecia 12
IR - Iran 12
NP - Nepal 12
PT - Portogallo 12
SK - Slovacchia (Repubblica Slovacca) 12
JM - Giamaica 11
MK - Macedonia 11
AL - Albania 10
LU - Lussemburgo 10
CR - Costa Rica 9
DZ - Algeria 9
TN - Tunisia 9
BG - Bulgaria 8
KG - Kirghizistan 8
LB - Libano 8
PA - Panama 8
HN - Honduras 7
PH - Filippine 7
TT - Trinidad e Tobago 7
CI - Costa d'Avorio 6
NI - Nicaragua 6
AM - Armenia 5
BA - Bosnia-Erzegovina 5
BH - Bahrain 5
GE - Georgia 5
LV - Lettonia 5
NO - Norvegia 5
PS - Palestinian Territory 5
RS - Serbia 5
TH - Thailandia 5
UG - Uganda 5
BO - Bolivia 4
BY - Bielorussia 4
CY - Cipro 4
DO - Repubblica Dominicana 4
KR - Corea 4
DK - Danimarca 3
LI - Liechtenstein 3
MD - Moldavia 3
MU - Mauritius 3
NZ - Nuova Zelanda 3
SI - Slovenia 3
SV - El Salvador 3
AO - Angola 2
Totale 36.555
Salva come PNG Salva come JPEG
Città #
Fairfield 1.572
Singapore 1.437
Ashburn 1.271
Hong Kong 1.171
Woodbridge 1.143
Jacksonville 1.090
Houston 829
Beijing 738
Cambridge 625
Seattle 600
Ann Arbor 587
Wilmington 577
Princeton 549
Chandler 477
New York 419
Los Angeles 404
Milan 370
Nanjing 351
Helsinki 326
The Dalles 316
Istanbul 300
Dublin 299
Chicago 248
Dallas 239
Munich 226
Brescia 218
Ho Chi Minh City 216
Rome 214
Warsaw 182
Buffalo 156
Moscow 152
São Paulo 138
Hanoi 131
Des Moines 127
Redondo Beach 127
Nanchang 122
San Diego 113
Florence 111
San Francisco 111
Hebei 105
Shenyang 105
Changsha 95
Shanghai 93
London 87
Tianjin 87
Salt Lake City 86
Turku 74
Jinan 72
Turin 69
Verona 65
Jiaxing 63
Trieste 61
Lancaster 58
Rio de Janeiro 57
Nuremberg 56
Tokyo 56
Brooklyn 55
Santa Clara 53
Hangzhou 52
Bologna 51
Johannesburg 47
Bergamo 46
Phoenix 46
Brussels 44
Montreal 44
Atlanta 43
Chennai 42
Dearborn 42
Genoa 40
Toronto 40
Denver 39
Guangzhou 39
Belo Horizonte 37
Elk Grove Village 37
Tampa 36
Stockholm 34
Udine 34
Kunming 33
Ningbo 33
Romola 33
Vienna 33
Padova 32
Poplar 30
Zhengzhou 30
Frankfurt am Main 29
Lappeenranta 29
Mexico City 28
Mumbai 28
Orem 28
Dhaka 27
Lanzhou 25
Amsterdam 24
Boardman 24
Falkenstein 24
Genova 24
Pisa 24
Salvador 24
Tallinn 24
Brasília 23
Curitiba 23
Totale 21.104
Salva come PNG Salva come JPEG
Nome #
ANTICORPI ANTI-TH/TO NELLA SCLEROSI SISTEMICA (SSC): CORRELAZIONI CLINICHE E IMMUNOLOGICHE 2.338
ANTICORPI ANTI-RNA POLIMERASI III: UN MARKER DI ESORDIO PRECOCE DI SCLEROSI SISTEMICA 1.772
Frequency Evaluation of the Interleukin-6 −174G>C Polymorphism and Homeostatic Iron Regulator (HFE) Mutations as Disease Modifiers in Patients Affected by Systemic Lupus Erythematosus and Rheumatoid Arthritis 684
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 396
Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease? 200
Anti-RNA polymerase III antibodies as a risk marker for early Gastric Antral Vascular Ectasia (GAVE) in systemic sclerosis 194
Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progression 187
Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study 187
Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI 184
Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2): Planted Antigens. 183
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study 177
Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS). 171
Macrophage activation syndrome in adult systemic lupus erythematosus: Report of seven adult cases from a single Italian rheumatology center 169
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) 169
Prevalence and disease-specific risk factors for Lower Urinary Tract symptoms in Systemic Sclerosis: an international multi-centric study 168
Endothelial Dysfunction In Early Systemic Lupus Erythematosus Patients And Controls Without Previous Cardiovascular Events. 166
Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies 165
C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis 163
Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences? 160
Endothelial dysfunction in early systemic lupus erythematosus patients and controls without previous cardiovascular events 159
Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus. 159
Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. 156
Antiphospholipid antibodies mediate autoimmunity against dying cells. 156
Systemic lupus erythematosus and endothelial dysfunction: A close relationship 155
Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. 155
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab 154
Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years 152
Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group 151
The clinico-serological spectrum of overlap myositis 151
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 151
Autoimmune polyendocrine Syndromes 149
Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality 149
Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study 149
Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures 147
Endothelial Dysfunction In Early Systemic Lupus Erythematosus Patients And Controls Without Previous Cardiovascular Events 147
Treatment and functional outcome of patients with cystoid macular edema: a single-center experience 146
The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study 146
Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept 146
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome 146
Antiphospholipid syndrome and glomerular thrombosis in the absence of overt lupus nephritis 143
Antinuclear antibodies in Frontotemporal Dementia: the tip's of autoimmunity iceberg? 143
Discordance for systemic lupus erythematosus and hyper IgE syndrome in a pair of monozygotic twins 142
Relationship between endothelial dysfunction, videocapillaroscopy and circulating CD3+CD31+CXCR4+ lymphocytes in systemic lupus erythematosus without cardiovascular risk factors 140
Aortic stiffness and left ventricular hypertrophy in rheumatoid arthritis: Comment on the article by Rudominer et al. 138
[Neonatal lupus: clinical features and risk of congenital cardiac heart block in newborns from mothers with anti Ro/SSA antibodies] 135
Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. 133
Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. 132
Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera 132
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome 132
Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis 131
Severe skin involvement in type II cryoglobulinemia successfully treated with thalidomide 129
The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies. 128
Autoantibodies to survival of motor neuron complex in patients with polymyositis: Immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins 128
Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus. 127
Rare autoantibodies to cellular antigens in systemic lupus erythematosus. 127
Anti-Ro/SSA and La/SSB antibodies 127
Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: The positive experience of a national multicentre study 127
Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women 126
Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus 125
Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase 124
Incidence of antiperinuclear factor in patients with psoriatic arthritis. 122
The 2016 classification criteria for primary Sjogren's syndrome: What's new? 122
Anti-topoisomerase-I antibodies in systemic lupus erythematosus and potential association with the presence of anti-dsDNA antibodies 121
Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients 121
METODICHE AUTOMATIZZATE PER ANTICORPI ANTINUCLEO (ANA): E' POSSIBILE SOSTITUIRE L'IMMUNOFLUORESCENZA INDIRETTA? 119
DECREASED TITER OF ANTI-CCP ANTIBODIES AND RHEUMATOID FACTOR AND REDUCTION OF POSTSWITCH MEMORY B CELLS AFTER ABATACEPT TREATMENT FOR RHEUMATOID ARTHRITIS 119
Belimumab decreases flare rate and hinders the expected damage progression in patients with active systemic lupus erythematosus 119
Myositis autoantibodies and clinical phenotypes 119
The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus 119
Multi-antibody composition in lupus nephritis: isotype and antigen specificity make the difference 118
Chilblain lupus erythematosus is associated with antibodies to SSA/Ro. 117
Deforming arthropathy of the hands in Systemic Lupus Erythematosus is associated with antibodies to SS-A/Ro and to SS-B/La. 117
A prospective evaluation of endothelial dysfunction in Systemic Lupus Erythematosus patients without previous cardiovascular events: preliminary results. 117
Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis 117
Pathogenetic associations of maternal anti-Ro/SSA antibodies. 116
Prognostic value of diastolic dysfunction in asymptomatic rheumatoid arthritis patients without cardiovascular risk factors 116
Celiac Disease Prevalence is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study 116
Antiperinuclear factor in psoriatic arthropathy 115
Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. 115
A prospective evaluation of endothelial dysfunction in systemic Lupus Erythematosus patients without previous cardiovascular events: preliminary results 115
Primary biliary cirrhosis-related autoantibodies in a large cohort of italian patients with systemic sclerosis 114
Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study 114
Elastic properties of the ascending aorta in patients with rheumatoid arthritis. 113
Determination of antibodies to extractable nuclear antigens by commercial kits: a multicenter study 113
In vivo reflectance confocal microscopy features of cutaneous microcirculation and epidermal and dermal changes in diffuse systemic sclerosis and correlation with histological and videocapillaroscopic findings. 113
Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. 112
75-SeHCAT retention test in chronic cholestatic disease: comparison with health and effect of bile acid therapy. 112
International cohort study of 73 anti-Ku-positive patients: Association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis 112
Update on Antiphospholipid Syndrome: Ten Topics in 2017 112
Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience. 112
Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. 111
A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies. 111
Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies. 111
The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus 111
Analysis of C9Orf72 Expansions in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Data 111
Systematic Review and Meta-analysis on the Association of Occupational Exposure to Free Crystalline Silica and Rheumatoid Arthritis 111
Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. 110
Serum prealbumin is an independent predictor of mortality in systemic sclerosis outpatients 110
Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies. 110
Disease course and obstetric outcomes of pregnancies in juvenile idiopathic arthritis: are there any differences among disease subtypes? A single-centre retrospective study of prospectively followed pregnancies in a dedicated pregnancy clinic 110
Totale 18.219
Salva come PNG Salva come JPEG
Categoria #
all - tutte 182.228
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 182.228
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.629 0 0 0 0 0 467 156 446 466 472 395 227
2021/20223.010 185 401 140 176 164 200 201 234 193 296 272 548
2022/20232.266 341 38 51 99 194 564 47 229 384 56 139 124
2023/20242.853 150 84 228 246 134 458 134 138 667 94 107 413
2024/20257.324 117 156 125 734 678 592 568 343 675 585 1.492 1.259
2025/20268.117 1.224 1.862 1.068 1.878 1.336 749 0 0 0 0 0 0
Totale 37.101